Teva : TEVA

All Teva Articles

450 Articles

Paul Ausick | Mar 17, 2016 at 4:04 PM EDT

The 52-Week Low Club for Thursday

March 17, 2016: Here are four stocks trading with heavy volume among 60 equities making new 52-week lows in Thursday’s…

Chris Lange | Mar 15, 2016 at 10:20 AM EDT

Huge Opportunity, and Risks, in 5 Top Abuse-Deterrent ER Opioids

One analyst firm believes the development of abuse-deterrent formulations (ADF) of opioids creates a risk that older non-ADFs may be…

Chris Lange | Mar 10, 2016 at 8:40 AM EST

Major Pharma Short Interest Takes a Small Step Back

The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Chris Lange | Feb 25, 2016 at 8:10 AM EST

Short Sellers Increase Bets in Major Pharma

The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Jon C. Ogg | Feb 14, 2016 at 9:32 AM EST

6 Biotech and Pharma Stocks Analysts Want You to Buy Now

Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside…

Chris Lange | Feb 10, 2016 at 9:15 AM EST

Short Sellers Increase Bets in Major Pharma

The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | Jan 28, 2016 at 8:40 AM EST

Short Sellers Become More Selective on Major Pharma

The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | Jan 13, 2016 at 9:15 AM EST

Major Pharma Short Sellers Increase Bets

The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks…

Jon C. Ogg | Jan 5, 2016 at 7:35 AM EST

Merrill Lynch Has 8 Top Stock Picks With Catalysts Coming in Q1 2016

Merrill Lynch has made many updates to its various lists, and one such list is the Top US Ideas for…

Jon C. Ogg | Jan 3, 2016 at 10:02 AM EST

10 Top 2016 Stock Picks From Goldman Sachs, Merrill Lynch and Other Key Analysts

Which well-known and large cap stocks to do the major analysts on Wall Street like for 2016? Here are 10.

Lee Jackson | Dec 29, 2015 at 10:55 AM EST

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current…

Chris Lange | Dec 28, 2015 at 9:35 AM EST

Major Pharma Short Interest Takes Another Giant Leap Forward

The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical…

Chris Lange | Dec 10, 2015 at 8:50 AM EST

Short Interest in Major Pharma Takes a Giant Leap

The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Jon C. Ogg | Nov 23, 2015 at 1:01 PM EST

Why Goldman Sachs Sees Serious Upside for Teva for 2016

Teva Pharmaceutical Industries Limited (NYSE: TEVA) had a very hard time getting off the ground from 2011 through the start…

Chris Lange | Nov 16, 2015 at 1:05 PM EST

What Perrigo and Teva Can Learn From Mylan’s Share Repurchase

Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster…

1 … 17 18 19 20 21 … 30

Teva : TEVA

All Teva Articles

The 52-Week Low Club for Thursday

Huge Opportunity, and Risks, in 5 Top Abuse-Deterrent ER Opioids

Major Pharma Short Interest Takes a Small Step Back

Short Sellers Increase Bets in Major Pharma

6 Biotech and Pharma Stocks Analysts Want You to Buy Now

Short Sellers Increase Bets in Major Pharma

Short Sellers Become More Selective on Major Pharma

Major Pharma Short Sellers Increase Bets

Merrill Lynch Has 8 Top Stock Picks With Catalysts Coming in Q1 2016

10 Top 2016 Stock Picks From Goldman Sachs, Merrill Lynch and Other Key Analysts

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

Major Pharma Short Interest Takes Another Giant Leap Forward

Short Interest in Major Pharma Takes a Giant Leap

Why Goldman Sachs Sees Serious Upside for Teva for 2016

What Perrigo and Teva Can Learn From Mylan’s Share Repurchase

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Teva : TEVA

All Teva Articles

The 52-Week Low Club for Thursday

Huge Opportunity, and Risks, in 5 Top Abuse-Deterrent ER Opioids

Major Pharma Short Interest Takes a Small Step Back

Short Sellers Increase Bets in Major Pharma

6 Biotech and Pharma Stocks Analysts Want You to Buy Now

Short Sellers Increase Bets in Major Pharma

Short Sellers Become More Selective on Major Pharma

Major Pharma Short Sellers Increase Bets

Merrill Lynch Has 8 Top Stock Picks With Catalysts Coming in Q1 2016

10 Top 2016 Stock Picks From Goldman Sachs, Merrill Lynch and Other Key Analysts

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

Major Pharma Short Interest Takes Another Giant Leap Forward

Short Interest in Major Pharma Takes a Giant Leap

Why Goldman Sachs Sees Serious Upside for Teva for 2016

What Perrigo and Teva Can Learn From Mylan’s Share Repurchase

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It